Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura.
about
Investigational drugs in thrombotic thrombocytopenic purpura.Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura?A case series of atypical presentations of thrombotic thrombocytopenic purpura.Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura.Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.Short- and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic purpura: four case reports.Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature.How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndromeApproach to management of thrombotic thrombocytopenic purpura at university of cincinnatiRituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.How we approach an acquired thrombotic thrombocytopenic purpura patient.Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.Long-term remission of recurrent thrombotic thrombocytopenic purpura (TTP) after Rituximab in children and young adults.How I treat refractory thrombotic thrombocytopenic purpura.Diagnosis and management of thrombotic thrombocytopenic purpura (TTP) in Australia: findings from the first 5 years of the Australian TTP/thrombotic microangiopathy registry.Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura.How we manage thrombotic microangiopathies in pregnancy.Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report.Efficacy and Safety of Rituximab for Refractory and Relapsing Thrombotic Thrombocytopenic Purpura: A Cohort of 10 Cases.Antibody therapy of pediatric B-cell lymphomaInfluence of plasma exchange on rituximab pharmacokineticsPopulation pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease.Management of thrombotic thrombocytopenic purpura: current perspectivesRituximab therapy in nephrotic syndrome: implications for patients' management.Medications and therapeutic apheresis procedures: are we doing our best?ABO-Incompatible Adult Living Donor Liver Transplantation Under the Desensitization Protocol With Rituximab.Rituximab treatment of myasthenia gravis: A systematic review.Biological Agents and Therapeutic Plasma Exchange: Can They Coexist in the Future?Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion.Post-Partum Thrombotic Thrombocytopenic Purpura (TTP) in a Patient with known Idiopathic (Immune) Thrombocytopenic Purpura: a case report and review of the literature.
P2860
Q33395696-53184972-FE81-49C5-B78B-BE9E5F37F1F4Q33395774-A974E061-02C2-4192-9AF8-56366A7A990FQ33400508-59BD12CC-2149-4C9D-909C-57261287EEABQ33400631-99E3A806-4500-4B9D-9459-6103BFD8AB49Q33401403-EE7BE3B5-4790-4D86-825A-F96FECF9182AQ33402749-42C84BFF-6A93-429F-BE3B-D60534999C96Q33404199-DE89BBDC-A899-4ECE-B9E0-DF0B39417EDFQ33412445-86643561-E5F5-42BA-B8FA-C38A72BECB9CQ33412498-AAC2E57A-23A4-4984-A4E3-DEBAA60EE0DCQ33416588-94D6B716-C08F-4887-AE91-6E851103D120Q33416780-90554772-9027-4543-806C-B07F142A6A9CQ33418352-810CEB5D-611C-4E4C-A74C-7CE135956964Q33419998-DB28D912-97F7-4E33-99DE-7168AD921275Q33421268-BDAD6B46-FC3E-4FB2-9708-F3612F466025Q33426823-F0F464F8-E29D-4E82-871D-9DCB2CFE6991Q33427885-5AF99D95-6F66-4A1A-A97E-B4B9B2B41A13Q33430243-83675C8C-A6E6-4A02-9661-60DF1295EAF8Q33431084-30C4D134-C44F-48ED-A205-C490026682B5Q34362680-8678A077-A95D-408E-9FF5-F9F8B104EC1BQ35672416-2D45FAB4-BDBB-4B25-B86C-8781433ED588Q36732959-A76F3A06-861F-4134-879F-D6A9D155FCD9Q37161921-5849A20C-AD77-46FE-A5F6-1C3DC5081815Q37369319-984D83F3-B2F8-4559-B7F5-71FFFFF54CC6Q37577785-877B14C0-6F71-4E3F-A499-448131B57468Q38075787-83F205DC-008F-4D70-9538-7A7D45D53621Q38082738-3E5A7527-2934-412A-BA26-C0500F20888DQ38422411-D64EB7B5-BEC6-45F0-8292-585BC3F7FAC7Q39121466-6BE9A3D4-47EF-46F3-9EDD-EF6349065E7EQ47800187-860C9E67-D160-4122-B496-C4747B68849DQ50707874-748AD4A1-1C67-4D90-B64C-179FF880A4D1Q55339707-1E00A547-9281-4D05-8DFC-073BB4119754
P2860
Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Rituximab pharmacokinetics dur ...... otic thrombocytopenic purpura.
@ast
Rituximab pharmacokinetics dur ...... otic thrombocytopenic purpura.
@en
type
label
Rituximab pharmacokinetics dur ...... otic thrombocytopenic purpura.
@ast
Rituximab pharmacokinetics dur ...... otic thrombocytopenic purpura.
@en
prefLabel
Rituximab pharmacokinetics dur ...... otic thrombocytopenic purpura.
@ast
Rituximab pharmacokinetics dur ...... otic thrombocytopenic purpura.
@en
P2093
P1476
Rituximab pharmacokinetics dur ...... otic thrombocytopenic purpura.
@en
P2093
P304
P356
10.1111/J.1538-7836.2010.03818.X
P577
2010-02-19T00:00:00Z